CytRx said this week that it has appointed Matthew Natalizio as the company’s chief financial officer.
In August last year, CytRx named Kirk Peacock as its CFO, but a CytRx spokeswoman told RNAi News that Peacock resigned effective June 15. Peacock continues to serve as a consultant to the company in order to assist in the transition to the new CFO, she added.
The spokeswoman declined to comment on the reasons behind Peacock’s departure, but his resignation comes after delays in the company’s filing of financial statements with the US Securities and Exchange Commission, as well as its dismissal of two independent auditors.
According to CytRx, Natalizio was most recently president and general manager of Cisco Brothers, a private furniture company. Before this, he was CFO at Qualstar. Natalizio has also served as a CPA and Ernst & Young, as well as a senior manager at KPMG.
CytRx said he holds a BA in economics from the University of California, Los Angeles.
Also this week, CytRx said that it has appointed Jack Barber as the company’s senior vice president of drug development.
Before joining CytRx, Barber was chief technical officer and vice president of research and development at Immusol. Prior to this, he worked in various positions at Viagene, which was acquired by Chiron, said CytRx.
Barber holds a BS and PhD in biochemistry from the UCLA, said CytRx.
Alnylam Pharmaceuticals said this week that Thomas Ulich, the company’s senior vice president of research and development, has resigned effective July 30 in order to “pursue other interests.”
“We thank Tom for his important contributions to Alnylam’s research effort over the past year and wish him the best,” John Maraganore, CEO of Alnylam, said in a statement.
“I believe that Alnylam is the pre-eminent company in the exciting field of RNA interference,” Ulich added in the statement. “I will miss the team there and look forward to following the company’s progress going forward.”
RNAi pioneer Craig Mello is scheduled to present an update on his work in C. elegans at the upcoming RNAiEurope conference, SelectConferences said this week.
Mello is currently a professor at the University of Massachusetts medical school and a Howard Hughes investigator. Mello holds a PhD from Harvard University and a bachelor’s degree in biochemistry from Brown University.
The conference is slated for Oct. 18 and 19 in London. Details about the event can be found at http://www.rnaieurope.com.